Despite the impressive development of medical therapies for patients with myocardial dysfunction, sudden cardiac death (SCD) is still too frequent. In patients with severe cardiomyopathies the insertion of an implantable cardiac defibrillator (ICD) has been shown to reduce SCD risk (1). For primary prevention in patients with left ventricular ejection fraction (LVEF) below 35%, ICD is now recommended (2). However, only 30% to 50% of implanted patients received appropriate ICD firings, and up to 25% suffered from side effects in the first year after ICD insertion (3,4). In addition, because of steadily growing demand for ICD replacements (5), the financial burden of primary ICD insertion on our healthcare systems is increasing. Consequently, there is an urgent need to improve the benefit-risk ratio of ICD insertion.
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The assessment of myocardial scarring with delayed enhanced cardiac magnetic resonance (DE-CMR) has become an important and independent prognostic factor of cardiovascular outcomes in various cardiomyopathies (6) . It is now established that myocardial scar and/or its correlates (scar pattern, relative size, heterogenous scar periphery size, transmurality) by DE-CMR are independent prognostic markers of cardiac death or ventricular tachycardia (VT) occurrence in patients with ischemic (7-12), nonischemic (13, 14) , and hypertrophic cardiomyopathies (15, 16) as well as in patients referred for ICD insertion (8, 17) . Simple myocardial scar assessment by DE-CMR is an accurate, reproducible, and reliable tool when put in trained hands. Therefore it could be reasonably integrated in addition to the precise measurement of LVEF by cardiac magnetic resonance imaging (MRI) (another advantage of cardiac MRI) in the therapeutic management of candidates for ICD insertion. With this in mind, the original article by Klem et al. (18) in this issue of the Journal is a cornerstone for the constitution of clinical trials integrating myocardial scar assessment by DE-CMR in the decision for ICD insertion.
In a prospective single-center cohort study on 137 patients referred for ICD insertion, Klem et al. (18) performed an expert and simple cardiac MRI study assessing myocardial scar and LVEF before implantation. The mean LVEF was 35 Ϯ 18%, and 75% (n ϭ 104) of the patients had an ICD placed, with an indication of primary prevention in 88%. Of the entire patient population, 78% (n ϭ 107) had scar by DE-CMR, while at the same time 76% (n ϭ 105) underwent an electrophysiology study with VT induction in 20% (n ϭ 21).
At 24 months, the primary endpoint occurred in 28% (n ϭ 39) of the patients with an approximately equal distribution of events between death and ICD discharge. Importantly, there were no patients lost to follow-up. The striking finding in this study is that there was a 5-fold increase in the rate of adverse events for a scar size Ͼ5% of the left ventricular (LV) mass and that scar size dichotomized approximately 5% of the LV mass provided a significant increment in prognostic value in addition to that of LVEF as assessed by integrated discrimination improvement and net reclassification improvement.
This work confirms and adds important information to prior reports in similar settings (8, 17) . However, it still does not provide any evidence on the value of LV scar assessment to help the physician decide whether a patient needs an ICD. To solve this question, prospective interventional trials in larger cohorts of patients will have to be built on the relatively solid ground set by the investigations of Klem et al. (18) and previous reports.
In addition to the relatively limited sample size and the single-center setting, other limits are that the investigators reported a relatively modest predictive value on SCD and ICD discharge of scar analyzed as a continuous variable (hazard ratio: 1.04, 95% confidence interval: 1.00 to 1.07, p ϭ 0.03). Except for an electrophysiological study in a large sub-group, no other electrophysiological variables were assessed (T-wave alternans, QT variability, signal averaged electrocardiogram, spatial QRS-T angle). Also, myocardial scarring or fibrosis can be caused by different mechanisms according to the underlying cardiomyopathy. Therefore there could be different types of fibrosis that could have a different arrhythmogenic impact. The mechanisms by which myocardial scars facilitate ventricular arrhythmias are not completely understood. It is accepted that the scarred tissue creates regions of slowed or incomplete electrical conduction that favor macro-reentrant circuits and, in turn, VT (9) . By contrast, the underlying mechanisms that yield to ventricular fibrillation are less clear.
Electrical instability is rarely the consequence of a single abnormality but of a group of factors that together lead to the fatal event. Consequently, the predictive values of single variables are not discriminant enough for arrhythmogenic profiling. New methods incorporating different parameters are needed to characterize ventricular electrical instability. Neuroimaging, genotyping, and quantitative analysis of ventricular repolarization with Holter recordings are promising (19 -22) . The work of Klem et al. shows that an accurate measurement of fibrosis by DE-CMR could be added to the list of noninvasive markers that will help to better risk-stratify patients with abnormal LVEF.
In the field of sudden death prediction, the complexity of arrhythmogenesis makes it necessary to take several parameters into account. The work of Klem et al. is a step toward a better selection of candidates for ICD insertion and also stresses the need for a multimodal approach to assess ventricular arrhythmia risk. The combination of data from cross-sectional imaging, neuroimaging, genotyping, and Holter analysis should make it possible to establish risk scores, increasing the relevance of ICD insertion. 
